Every tumor is unique. Thus, it is essential to know and understand the underlying molecular pathology of a tumor to treat it properly. With comprehensive genomic profiling (CGP), hundreds of genes and cancer-relevant biomarkers can be analyzed simultaneously. The chances of discovering actionable alterations are increased by simultaneously assessing all these genes and biomarkers. With this approach, results might be available faster, and input material of biopsy samples can be saved. One possibility to comprehensively profile a tumor is the TruSight™ Oncology 500 Assay. With this assay, 523 cancer-relevant genes are analyzed for single nucleotide variants (SNVs), insertions and deletions (indels), and copy number variations (CNVs). Furthermore, the cancer-relevant biomarkers tumor mutational burden (TMB) and microsatellite instability (MSI) are assessed. TMB measures the number of somatic mutations in a cancer patient’s tumor and is quantified as mutations per megabase (mut/Mb). MSI indicates failures of the DNA mismatch repair system.
The application areas of TSO500 are manifold and include:
- Stratifying patients for the best treatment choice
- Identifying patients eligible for clinical trials
- Driving clinical research, especially in the area of immune therapy
You can choose between different TSO500 products for comprehensive genomic profiling of your tumor samples.